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Volume 56, Number 4 Abstracts 1181Comment:At this point, vascular surgeons are not likely to be involved
with the selection of patients for TAVI. However, TAVI will become more
widely performed in the U.S. during the next few years as approved devices
are gradually disseminated to selected hospitals. Because the devices can
require large introducer sheaths (up to 24F) and the transapical approach
appears to be associated with higher mortality, vascular surgeons may be
involved with selection of access for placement of these devices and treat-
ment of the complications of transfemoral or trans-subclavian access. At this
point, major vascular complications in patients undergoing TAVI via the
transfemoral approach appear to occur in about 5.5% of the cases. It also
appears that in Europe, patients are increasingly opting for TAVI rather than
open aortic valve replacement, and there are suggestions of a high rate of
off-label use of the device (Zahn R et al, Eur Heart J 2011;32:198-204).
Vascular surgeons should be aware of the complexity of these patients, access
options, and the complications and outcomes of TAVI.
Stroke Recurrence Within the Time Window Recommended for Ca-
rotid Endarterectomy
Marnane M., Chroinin DN., Callaly E., et al. Neurology 2011;77:738-43.
Conclusion: Patients with asymptomatic carotid stenosis (CS) can
have recurrent strokes within the recommended treatment period of 14 days.
Summary:There is time-dependent benefit of surgery for patients with
symptomatic CS, with maximum benefit when treatment is within 2 weeks
and minimal benefit for those treated after 12 weeks (Rothwell PM et al,
Lancet 2004;363:915-24). Multiple guidelines from surgical and medical
societies now recommend endarterectomy within 14 days of symptoms
referable to a cervical CS. There are however, only a few population based
studies regarding the risk of stroke recurrence within the 14-day period
recommended for endarterectomy (Fairhead JF et al, Neurology 2005;65:
371-5). No population-based studies have evaluated recurrence risk within
72 hours of symptoms. In this study, the authors hypothesized ischemic
stroke associated with CS would have a high early recurrence rate. They
attempted to qualify this recurrence rate by using a population-based pro-
spective cohort study design with patients from the North Dublin popula-
tion stroke study. Ischemic strokes were identified over a 1-year period and
categorized into those with and without CS, with CS defined as an ipsilateral
CS with50% luminal narrowing. Stroke recurrence not associated with any
procedure was determined at 72 hours and at 7 and 14 days. A total of 365
patients had an ischemic stroke and carotid imaging. There were 51 exclu-
sions because the stroke involved the posterior circulation, was nonlateral-
izing, or was associated with ipsilateral carotid occlusion or an intracranial
CS. Of the 314 patients included for analysis, there were 36 CS-positive and
278 CS-negative strokes. Recurrent stroke occurred in 5.6% (2 of 36) of
CS-positive patients and in 0.4% (1 of 278) of CS-negative patients within
72 hours of symptom onset (P .003). At 7 days, recurrent stroke occurred
in 5.6% (2 of 36) of CS-positive patients and in 0.7% (2 of 278) of
CS-negative patients (P  .001). At 14 days, recurrent stroke occurred in
8.3% (3 of 36) of CS-positive patients and in 1.8% (5/278) of CS-negative
patients. With multivariable Cox regression analysis, CS was the only inde-
pendent predictor of recurrence at 72 hours (adjusted hazard ratio [HR],
36.1; 95% confidence interval [CI], 1.6-837.5; P  .03) and was also the
only independent predictor of recurrence at 7 days (HR, 9.1; 95% CI,
1.1-79.2; P  .05). There was also a trend at 14 days for CS being an
independent predictor of recurrence (HR, 4.6; 95% CI, 0.9-22.8; P .06).
Comment: The data indicate that in some stable patients who are
suitable candidates for endarterectomy, urgent surgery within a few days of
symptoms may prevent early stroke recurrence. A recent systematic review
also concluded there is no difference in risk of stroke or death in neurologic
stable patients who undergo endarterectomy within 1 week compared with
c
tlater time (Rerkasem K, Rothwell PN, Stroke 2009;40:e564-72). The
bvious limitation of the data here is the low number of recurrent events,
esulting in statistically significant conclusions but with wide confidence
ntervals. Additional population-based studies looking at early stroke recur-
ence are required to confirm the relatively weak statistical conclusions of this
eport.
enous Thrombosis in Users of Non-Oral Hormonal Contraception:
ollow-Up Study, Denmark 2001-10
idegaard O., Nielsen LH., Skovlund CW., et al. BMJ 2012;344:e2990
doi: 10.1136/bmj.e2990].
Conclusion:Women who use transdermal patches or vaginal rings for
ontraception have approximately a six to seven times increased risk of
enous thromboembolism (VTE) compared to women who do not use
ormonal contraception.
Summary: It is well known oral contraceptive agents increase the risk
f VTE. There are, however, little to no data regarding the effects of
ethods other than pills to deliver hormonal contraceptive agents. Such
ethods include transdermal patches, subcutaneous implants, and vaginal
ings. The authors used a historic national registry in a cohort study design
o assess absolute and relative risk of VTE in Danish women using nonoral
ormonal contraception. This national registry-based cohort study used
our national registries from Denmark. All Danish nonpregnant women
ged 15 to 49 years (n  1,626,158), who were free of previous VTE or
ancer, were followed up from 2001 to 2010. The main outcome measures
ere incidence rates of VTE in users of transdermal, vaginal, intrauterine, or
ubcutaneous hormonal contraception. Relative risk of venous thrombosis
as compared with nonusers of hormonal contraception, and rate ratios of
enous thrombosis in current users of nonoral products were compared with
he standard reference of an oral contraceptive with levonorgestrel and
strogen (30-40 g). A diagnosis of VTE was considered confirmed if there
as at least 4 weeks of anticoagulation therapy after the initial VTE diagno-
is. There were 5,287 first ever VTE events recorded within 9,429,128
omen-years of observation. Of these VTE events, 3,434 were confirmed.
he rate of confirmed VTE events was 2.1/10,000 years in nonusers of
ormonal contraception. After adjustment for age, calendar year, and edu-
ation, the relative risks and 95% confidence interval (95% CI) of confirmed
TE in users of transdermal combined contraceptive patches and vaginal
ing compared with nonusers of hormonal contraception were 7.9 (3.5-
7.7) and 6.5 (7.4-8.9), respectively. Corresponding incidence events per
0,000 exposure-years were 9.7 and 7.8 events. The relative risk (95% CI)
as increased in women who used subcutaneous implants (1.4 [0.6-3.4])
ut not in those who use the levonorgestrel intrauterine system (0.6 [0.4-
.8]). Compared with users of combined oral contraceptives containing
evonorgestrel, the adjusted relative risk (95% CI) of VTE was 2.3 (1.0-5.2)
n users of transdermal patches and 1.9 (1.3-2.7) in users of the vaginal ring.
Comment: In the last paragraph of the discussion portion of this article
he authors succinctly point out the implications of their study, “if the
ncidence rate of venous thrombosis in women using combined oral contra-
eptives containing levonorgestrel is 6 per 10,000 exposure years, that of the
aginal ring is 11 per 10,000 exposure years, and that of the transdermal
atch is 14 per 10,000 exposure years, then 2000 women using the vaginal
ing, and 1250 using the transdermal patch should shift to combined oral
ontraceptives with levonorgestrel to prevent 1 event of VTE in one year. A
isk of 10 per 10,000 years implies a risk of VTEmore than 1% over a 10 year
ser period. Therefore, women are generally advised to use combined oral
ontraceptives with levonorgestrel or norgestimate, rather than to use
ransdermal patches or vaginal rings.”
